Comparison of Secukinumab Vs Infliximab in a Cost Per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthrisis at 48 Weeks from a Moroccan Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.746
https://www.valueinhealthjournal.com/article/S1098-3015(17)31080-X/fulltext
Title :
Comparison of Secukinumab Vs Infliximab in a Cost Per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthrisis at 48 Weeks from a Moroccan Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31080-X&doi=10.1016/j.jval.2017.08.746
First page :
A530
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
712